Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 3763 3767 3783 4100
This examiner grants 58% of resolved cases
Shefali Dilip Patel serves in Tech Center 4100 and Art Unit 3763. The examiner has 752 resolved cases and an allowance rate of 58.0 percent. This 58.0 percent rate suggests a moderate path to allowance for applications in this unit.
The interview lift is 27.7 percent. This positive lift suggests that interviews are an effective tool for advancing prosecution. When compared to the 58.0 percent base allowance rate, the 27.7 percent lift shows that direct communication with the examiner can substantially improve the probability of a successful outcome.
The median days to allowance is 1413. This timeline represents the typical duration for applications to reach a grant. While the 1413 day period is relatively long, the 27.7 percent interview lift offers a clear path to potentially improve the 58.0 percent chance of success and navigate the prosecution more effectively in Art Unit 3763.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18450075 | MEDICAL DEVICES AND RELATED METHODS | Final Rejection | Boston Scientific Scimed, Inc. |
| 18105533 | Intraosseous Hemodialysis Port | Non-Final OA | Bard Access Systems, Inc. |
| 18709991 | SENSOR ARRANGEMENT FOR A BREAST PUMP DEVICE AND BREAST PUMP DEVICE USING THE SENSOR ARRANGEMENT | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 17603315 | CUSHION CONFIGURED TO BE MOUNTED TO AN AIR PASSAGE ELEMENT OF A BREAST PUMP DEVICE | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 18684025 | THERAPEUTIC AGENT DELIVERY DEVICE | Non-Final OA | ELI LILLY AND COMPANY |
| 18144799 | PRESSURE REGULATOR FOR OCULAR SURGERY | Final Rejection | JOHNSON & JOHNSON SURGICAL VISION, INC. |
| 18616678 | SURFACE TREATMENT FOR CONNECTORS | Non-Final OA | CareFusion 303, Inc. |
| 17799541 | DRUG INFUSION DEVICES COMPATIBLE WITH DRUG FORMULATIONS | Non-Final OA | Medtronic, Inc. |
| 18397853 | FLOW DIVERTER FOR A CATHETER | Non-Final OA | Biosense Webster (Israel) Ltd. |
| 16944588 | SYSTEMS AND METHODS THAT FACILITATE TATTOO REMOVAL | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18254494 | NEEDLE AND SYRINGE USING SAME | Final Rejection | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18657274 | Instrument Advancement Device with Light-Enabled Instrument Viewing | Non-Final OA | Becton, Dickinson and Company |
| 18618940 | PASSIVE SAFETY CATHETER SYSTEM AND RELATED METHODS | Non-Final OA | Becton, Dickinson and Company |
| 18431170 | INJECTION PEN | Non-Final OA | Becton, Dickinson and Company |
| 17297604 | INTEGRATED CONNECTOR AND DISINFECTING CAP WITH RESERVOIR | Non-Final OA | Becton, Dickinson and Company |
| 18694079 | DRIVING AN OPTICAL SENSOR OF A DRUG DELIVERY DEVICE OR OF A DRUG DELIVERY ADD-ON DEVICE | Non-Final OA | Sanofi |
| 18289008 | Coded Housing Components for an Injection Device | Final Rejection | Sanofi |
| 18287256 | HOUSING COMPONENTS AND MEDICAMENT CONTAINER FOR AN INJECTION DEVICE | Final Rejection | Sanofi |
| 18475927 | Injector Device | Final Rejection | Sanofi |
| 18450238 | SAFETY AND ACCURACY MEASURES FOR MEDICAMENT BOLUS DELIVERY | Final Rejection | INSULET CORPORATION |
| 18293959 | A subassembly of a medicament delivery device | Final Rejection | SHL Medical AG |
| 18336880 | Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And FGF Inhibitors | Final Rejection | NOVOCURE GMBH |
| 18674549 | INJECTION DEVICE FOR DRUG DELIVERY AND PACKAGING FOR THE INJECTION DEVICE | Final Rejection | AMGEN INC. |
| 18710112 | PLUNGER ROD REMOVAL FORCE METHOD AND FIXTURE | Non-Final OA | AMGEN INC. |
| 17859260 | THREE-WAY UROLOGY CATHETER STOPCOCK AND UROLOGY CATHETER STOPCOCK ASSEMBLY | Non-Final OA | The University of Toledo |
| 18703719 | DRUG INFUSION DEVICE WITH INTEGRATED POWER SUPPLY AND ARTIFICIAL PANCREAS | Non-Final OA | MEDTRUM TECHNOLOGIES INC. |
| 18294822 | BREAST CONTACTING ELEMENT | Non-Final OA | MAYBORN (UK) LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy